Syncordia Technologies and Healthcare Solutions, Corp. Reports Third Quarter Fiscal 2017 Results

TORONTO, Feb. 23, 2017 /CNW/ - Syncordia Technologies and Healthcare Solutions, Corp. (TSXV: SYN) ("Syncordia" or the "Company") today reported financial results for the three and nine months ended December 31, 2016.

Reported results reflect nine months of operations of Health Services Integration Inc. ("HSI"), which was acquired effective October 31, 2014, Paragon Billing LLC, ("Paragon") which was acquired April 24, 2015, and Billing Solutions LLC ("Billing Solutions"), which was acquired March 22, 2016. All results are reported in thousands of US dollars and are prepared in accordance with International Financial Reporting Standards ("IFRS").

Management Commentary

Along with the Company's refinancing efforts, Syncordia continues to evaluate various strategic alternatives including, but not limited to, the divestiture of a portfolio company to reduce debt and put additional cash on the balance sheet.  The Company believes these steps will unlock the value that exists in the enterprise and allow Syncordia to expand further in the healthcare software industry. We maintain a good relationship with our lenders and are keenly focused on operational excellence to unlock the value of our underlying assets. Recent organic wins, operational throughput enhancements have added top line revenue and additional margin driving bottom line profits. We continue to evaluate targets for acquisition and organic growth as well as development of new software products to enhance shareholder value. All of these details have recently been press released and available in greater detail on the investor news section of our website.

HSI reduced its average cost per ground claim to $19 compared to $21 in the second quarter. We continue to enhance operations moving toward our target cost of $8 to $10 per ground claim.  Cost per air claim at HSI increased from $84 in the second quarter to $97 in the third quarter.  This increase is attributable to a 20% decrease in air/SCT volume quarter over quarter.   We have taken steps to reduce cost per air claim and are targeting $60 per claim.

Year to date, we have reduced our staff headcounts by approximately 40 individuals in our RCM segment, including a reduction of ten FTEs at HSI in the third quarter. As at December 31, 2016, we had 109 FTEs across our portfolio companies.  In addition, we continue to rationalize corporate and Platform Syncordia headcounts, reducing our FTEs at Syncordia Ireland by three in the third quarter.

Business Highlights

  • Obtained a waiver from senior lending consortium, resulting in reduced principal payment of $1.35 million in November 2016 instead of $2.22 million in order to maintain adequate flexibility and liquidity for working capital needs. The shortfall of $0.88 million will be added to the May 2017 principal repayment.

  • The Company is pursuing a number of alternatives with regard to refinancing our senior debt.

  • Management is exploring strategic alternatives, including but not limited to (i) the sale of portfolio RCM company or companies (ii) strategic alliances with HSI to improve overall results (iii) licensing or sale of certain intellectual property (iv) other cash-generating initiatives. Syncordia maintains three operating businesses that we anticipate could be sold at favorable multiples and would maximize value as Platform Syncordia and Corporate costs would not be required by the new owners in the event of a sale.

  • HSI is implementing several operational initiatives anticipate to add over $1.0 million to the bottom line on an annualized basis, expected to be realized by first quarter fiscal 2018.  In addition, HSI is onboarding new contracts over the coming months and quarters while continuing to convert additional pipeline opportunities.

  • Billing Solutions is in the process of signing customer contracts expected to contribute an additional $0.3 million in EBITDA on an annualized basis.

  • Paragon signed a customer contract with expected volume of 50,000 annual encounters. This contract commenced in February 2017.

  • Syncordia is introducing Claim Editor and additional staff in its lower cost Maryland billing center to further reduce cost per claim.

  • Announced NECTAR version 2.0, a client analytics portal for our behavioural health customers, consisting of a business intelligence dashboard showing key medical practice performance indicators. Syncordia continues to focus on building out its full service software suite for Billing Solutions.

 

Third Quarter 2017 Compared to Third Quarter 2016

  • Revenue decreased $277 or 8%, $1,216 of which is attributable to REACH Air Medical Holdings and affiliated entities as we wind down the provision of billing services to this customer group as well as other payor mix changes at HSI, offset by $1,428 which was attributable to the acquisition of Billing Solutions.

  • Gross margin decreased from 73% to 59% of revenue primarily reflecting a lower portion of our revenue from higher margin air transports.

  • Net loss and comprehensive loss was $1,345 compared to a loss of $601 in the comparative period, reflecting a $277 reduction in revenue and $527 increase in cost of sales.

  • Adjusted EBITDA before Platform Syncordia and Corporate costs decreased $831 or 50% primarily reflecting lower revenues at HSI.

  • Platform Syncordia costs decreased $176 or 42%, excluding $245 of capitalized development costs during the three months ended December 31, 2016. Total Platform Syncordia spend reflects our software development efforts as we continue to develop Platform Syncordia.
  • Corporate costs decreased $81 or 15% reflecting several cost reduction initiatives.

  • Adjusted EBITDA was $130, before accounting for non-controlling interests.

  • Cash and cash equivalents of $1,121.

 

Third Quarter 2017 Financial Highlights

  • Revenue was $3,401 and is segmented by RCM business as follows - $1,543 HSI, $430 Paragon and $1,428 Billing Solutions

  • Adjusted EBITDA was $130, reflecting our 80% interest in Billing Solutions.

  • Cash and cash equivalents of $1,121.

 

Key Performance Indicators
We report Encounters as a key performance indicator to assist readers in better evaluating our performance. We define an Encounter as a discrete business activity for which we would submit a claim. We believe this metric provides investors with a better proxy for measuring the level of business activity than revenue as encounters measure the number of distinct services provided in the period whereas revenue reflects the amount of services recognized for accounting purposes and is typically a lagging indicator of business activity.

 



Encounters

Sequential Quarterly Change


Quarter

Q1

FY2017

Q2

 FY2017

Q3
FY2017

YTD
FY2017

 

#

%










Air/SCT

2,744

3,903

3,125

9,772

(778)

(20%)










Ground

7,202

12,231

15,708

35,141

3,477

28%










HSI

9,946

16,134

18,833

44,913

2,699

17%










Paragon

82,430

63,809

65,737

211,976

1,928

3%










Billing Solutions

46,697

48,052

45,697

140,446

(2,355)

(5%)










 

 

HSI encounters increased 17% reflecting the on-boarding of Mercy Health North LLC and LACP/St. Rita's Medical Center. Specialty Care Transport (SCT) encounters were 245, 901, and 462 in in the first, second and third quarters, respectively. Paragon encounters increased 1,928 or 3% as we begin to onboard new customers. Billing Solutions encounters decreased 5% primarily as a result of seasonality.

Notice of Conference Call
Syncordia will hold a conference call on Friday, February 24, 2017, at 8:00 a.m (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through www.syncordiahealth.com or http://event.on24.com/r.htm?e=1362075&s=1&k=FDD63B34F7F8568172D50022B42EA90C. An archived replay of the webcast will be available for 90 days. A presentation will accompany the conference call and will be available for download from the Investor Relations section of Syncordia's website at: http://www.syncordiahealth.com/company/investor-relations/events-presentations/.

Forward Looking Statements
Certain statements herein may be "forward looking" statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Syncordia or the industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward looking statements. These forward looking statements reflect current assumptions and expectations regarding future events and operating performance and are made as of the date hereof and we assume no obligation, except as required by law, to update any forward looking statements to reflect new events or circumstances.

Cautionary Note Regarding Non-IFRS Measures
This press release contains references to "EBITDA," "Adjusted EBITDA," "Gross margin," and "Adjusted EBITDA before Platform Syncordia and Corporate costs."

Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") and Adjusted Earnings before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") are non-IFRS measures used by management to provide additional insight into our performance and financial condition.  We believe that these non-IFRS measures are important as they provide an indication of the results generated by our RCM business prior to taking into consideration how those activities are financed as well as the other items listed in their respective definitions.  Accordingly, we are presenting EBITDA, Adjusted EBITDA and Adjusted EBITDA before Platform Syncordia and Corporate costs in this MD&A to enhance the usefulness of our MD&A. We have provided below a reconciliation of EBITDA, Adjusted EBITDA and Adjusted EBITDA before Platform Syncordia Corporate costs to the most directly comparable IFRS figures, disclosure of the purpose of the non-IFRS measure, and how the non-IFRS measures is used in managing the business.

EBITDA, Adjusted EBITDA and Adjusted EBITDA before Platform Syncordia and Corporate costs are not calculations based on IFRS and should not be considered an alternative to operating income or net income (loss) in measuring the our performance, nor should it be used as an exclusive measure of cash flow, because it does not consider the impact of working capital growth, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in the consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of these measures.

Management defines EBITDA as Earnings before Interest, Taxes, Depreciation and Amortization.

Management defines Adjusted EBITDA as Earnings before Interest, Taxes, Depreciation, Amortization, Transaction Costs, Fair Value Gains/Losses, Foreign Exchange Gains/Losses, Stock Based Compensation and Cash based Share Compensation Arrangements. Transaction costs include professional fees associated with business transactions.

Management defines Adjusted EBITDA before Platform Syncordia and Corporate costs as Earnings before Interest, Taxes, Depreciation, Amortization, Transaction Costs, Fair Value Gains/Losses, Foreign Exchange Gains/Losses, Stock Based Compensation, Cash based Share Compensation Arrangements and costs of our Platform Syncordia and Corporate segment. This metric is used to assess the performance of RCM and Platform Syncordia segments.

Gross margin is a non-IFRS measure defined by management to reflect revenue less direct cost of sale, excluding amortization of intellectual property, customer lists, other amortizations and fair value gains/losses.

Platform Syncordia and Corporate costs include sales and marketing, general and administrative and research and development, less amortization and depreciation, foreign exchange gains and losses, and stock-based compensation expense indexed to our share price.

About Syncordia Technologies and Healthcare Solutions, Corp.
We are a technology enhanced revenue cycle management ("RCM") company focused on underserved niche segments of the healthcare industry. We are building a diversified software and services business by consolidating healthcare billing providers. Our growth strategy is to acquire RCM businesses with and without software and, improve their profitability by increasing revenues and operating efficiencies using our software, and in time, commercializing Platform Syncordia, our cloud-based software offering, to provide customer demanded turn-key solutions from a single provider and to address compelling RCM market opportunities. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

The following is a reconciliation of EBITDA with net loss and comprehensive loss:
(in thousands of US Dollars)






Three Months ended

Three Months ended

Nine Months ended


Dec 31

2016

Dec 31

2015

Dec 31

2016

Sep 30

2016

Dec 31

2016

Dec 31

2015

 

Net loss and comprehensive loss

(1,345)

(601)

(1,345)

(1,594)

(4,514)

(1,929)

Amortization of operating and other
assets

989

774

989

939

2,858

2,275

Income tax expense (recovery)

(59)

-

(59)

(60)

(147)

-

Interest expense

510

478

510

530

1,563

1,397

EBITDA

95

651

95

(185)

(241)

1,743

 

The following is a reconciliation of Adjusted EBITDA and Adjusted EBITDA before Platform Syncordia and Corporate costs with Net loss and comprehensive loss:
(in thousands of US Dollars)

 

 






Three Months ended

Three Months ended

Nine Months ended


Dec 31

2016

Dec 31

2015

Dec 31

2016

Sep 30

2016

Dec 31

2016

Dec 31

2015

 

Net loss and comprehensive loss

(1,345)

(601)

(1,345)

(1,594)

(4,514)

(1,929)

Amortization of operating and other
assets

989

774

989

939

2,858

2,275

Income tax expense (recovery)

(59)

-

(59)

(60)

(147)

-

Interest expense

510

478

510

530

1,563

1,397

Transaction costs

19

17

19

-

20

1,786

Foreign exchange (gains) and losses

6

12

6

-

9

146

Unrealized (gains) and losses on
derivative financial liability

-

(1)

-

-

-

(608)

Realized gain on contingent
consideration

-

-

-

-

-

(1,111)

Stock based compensation

10

25

10

9

30

75

Adjusted EBITDA (i)

130

704

130

(176)

(183)

2,031

Platform Syncordia costs (i)

244

420

244

393

1,124

1,114

Corporate costs (i)

469

550

469

546

1,500

1,804

Adjusted EBITDA before Platform
Syncordia and Corporate costs (i)

843

1,674

843

763

2,442

4,949

Notes:

(i) Non-IFRS measure, Platform Syncordia and Corporate costs exclude stock based compensation, transaction costs, foreign exchange gains and loss, fair value adjustments, and amortization.

 

Syncordia Technologies and Healthcare Solutions, Corp.
Condensed Interim Consolidated Statements of Financial Position
As at December 31, 2016 and March 31, 2016






December 31
2016

March 31

2016




Assets






Current assets




Cash and cash equivalents

1,121,203

4,436,844


Accounts receivable

2,152,578

2,226,715


Other assets

303,529

377,185





3,577,310

7,040,744




Property and equipment

429,196

338,622




Intangible assets

20,397,586

22,694,613




Goodwill

10,758,996

10,781,769





35,163,088

40,855,748




Liabilities






Current liabilities




Accounts payable and accrued liabilities

1,755,070

1,584,735


Holdback payable

-

250,000


Current portion of notes payable

11,675,806

2,222,065





13,430,876

4,056,800




Notes payable

2,000,000

12,350,631




Deferred tax liabilities

1,746,103

1,932,097




Other non-current liabilities

272,329

133,076





17,449,308

18,472,604




Shareholders' Equity






Share capital

25,529,338

25,517,330




Contributed surplus

1,996,384

1,963,529




Deficit

(10,773,339)

(6,010,506)


Equity attributable to shareholders of Syncordia

16,752,383

21,470,353


Non-controlling interests

961,397

912,791


17,713,780

22,383,144





35,163,088

40,855,748




 

Syncordia Technologies and Healthcare Solutions, Corp.  
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss
For the three and nine months ended December 31, 2016 and 2015

 





Three months ended

December 31

Nine months ended

December 31


2016

2015

2016

2015






Revenue

3,400,716

3,678,236

11,134,903

10,969,933






Gain on settlement of contingent consideration

-

-

-

1,111,342


3,400,716

3,678,236

11,134,903

12,081,275






Cost of sales

1,390,854

996,161

4,591,061

3,088,326






Amortization of operating assets

841,416

708,368

2,542,057

2,077,351


1,168,446

1,973,707

4,001,785

6,915,598






Operating expenses

1,895,662

2,016,429

6,765,295

6,072,616






Transaction costs

18,824

16,742

19,740

1,786,170






Other amortization

147,417

65,332

315,552

197,618

Loss before financing and tax expenses

(893,457)

(124,796)

(3,098,802)

(1,140,806)






Change in fair value of derivative financial liability

-

(1,026)

-

(608,987)






Interest expense

509,747

477,594

1,562,546

1,397,237






Net loss before tax

(1,403,204)

(601,364)

(4,661,348)

(1,929,056)






Income tax expense (recovery)

(58,673)

-

(147,121)

-






Net loss and comprehensive loss for the period

(1,344,531)

(601,364)

(4,514,227)

(1,929,056)






Net loss and comprehensive loss attributable to:







Shareholders of Syncordia

(1,455,609)

(601,364)

(4,762,833)

(1,929,056)



Non-controlling interests

111,078

-

248,606

-






Net loss per share






Basic and diluted earnings per share

(0.07)

(0.03)

(0.23)

(0.11)






Weighted average number of shares outstanding






Basic

19,681,135

19,643,635

19,658,499

18,291,004


Diluted

19,681,135

19,673,670

16,658,499

18,321,039

 

Syncordia Technologies and Healthcare Solutions, Corp.
Condensed Interim Consolidated Statements of Cash Flows
For the three and nine month periods ended December 31, 2016 and 2015





Three months ended

December 31

Nine months ended

December 31


2016

2015

2016

2015






Cash provided by (used in)










Operating activities





Net loss for the period

(1,344,531)

(601,364)

(4,514,227)

(1,929,056)

Items not affecting cash






Gain on settlement of contingent consideration

-

-

-

(1,111,342)


Reverse Takeover transaction costs

-

-

-

1,068,920


Deferred income tax expense (recovery)

(60,040)

-

(185,994)

-


(Gain)/loss on derivative liability

-

(1,026)

-

(608,987)


Amortization

988,832

773,700

2,857,609

2,274,969


Non-cash interest on notes payable

214,168

171,473

647,386

500,361


Share-based compensation and awards

10,181

25,231

30,317

75,239

Changes in non-cash working capital items






Accounts receivable

189,884

246,123

74,138

329,687


Other assets

(67,115)

(108,198)

73,655

(180,260)


Accounts payable and accrued liabilities

32,795

(274,184)

(112,490)

(338,205)


Other non-current liabilities

1,211

43,590

3,453

127,429


(34,615)

275,345

(1,126,153)

208,755






Investing activities





Purchase of property, equipment and intangible assets

 

(66,622)

 

(34,966)

 

(170,689)

(158,496)

Capitalized software development costs

(245,000)

-

(245,000)

-

Working capital settlement for acquisition of Billing
Solutions

 

-

 

-

 

22,773

-

Acquisition of Paragon (net of cash acquired)

-

-

-

(3,479,929

Settlement of Paragon holdback

-

-

(250,000)

(250,000)

Settlement of contingent consideration

-

-

-

(1,208,658)


(311,622)

(34,966)

(642,916)

(5,097,083)






Financing activities





Issuance of Class B Series 2 preferred shares

-

-

-

3,405,000

Issuance of private placement

-

-

-

8,052,460

Cash consideration from issuance of Reverse Takeover
shares

 

-

 

-

 

-

402,605

Share issuance costs

-

-

-

(831,560)

Proceeds from long-term notes

-

-

-

1,332,388

Repayment of notes payable

(1,346,572)

-

(1,346,572)

-

Deferred financing costs

-

-

-

(29,960)

Distributions to non-controlling interest

(160,000)

-

(200,000)

-


(1,506,572)

-

(1,546,572)

12,330,933






Increase/(decrease) in cash and cash equivalents
during the period

 

(1,852,809)

 

240,379

 

(3,315,641)

7,442,605






Cash and cash equivalents - Beginning of period

2,974,012

10,044,639

4,436,844

2,842,413

Cash and cash equivalents - End of period

1,121,203

10,285,018

1,121,203

10,285,018






Cash interest paid

295,580

307,616

915,170

899,816

 

SOURCE Syncordia Technologies and Healthcare Solutions, Corp.



For further information: Michael Franks, Chief Executive Officer, (647) 949-2663, mike.franks@syncordiahealth.com

RELATED LINKS
www.syncordiahealth.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890